IDEAYA Biosciences, Inc.
NASDAQ:IDYABiotechnology
-$0.45 today
- Market cap
- $2.56B
- Beta
- -0.05
- P/E (TTM)
- -19.5
- EPS (TTM)
- -$1.58
Volume 1.45M
Average 1.44M
IDYA Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
IDEAYA Biosciences, Inc.NASDAQ: IDYA
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue remains negative
Q1 FY2026 revenue was $6.56M, compared with $0 a year earlier. Trailing-twelve-month revenue was $225.27M. Over 3 fiscal years it compounded at +62.5% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 11 analysts of $45.54M (-79.2%) for the fiscal year ending Dec 2026, a slowdown from the +3024.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.56M-39.7% QoQ
- Last fiscal yearDec 2025
- $218.71M+3024.4% YoY
- LTMMar 2026
- $225.27M+3118.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +3024.4% | -79.2% | -3103.6 pp |
| 3-year CAGR | +62.5% | +7.3% | -55.2 pp |
| 5-year CAGR | +32.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 218.71M USD
- Year-over-year change
- +3024.4%
- 4-year CAGR
- +67.3%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 218.71M | +3024.4% |
| FY2024 | 2024-12-31 | 7M | -70.1% |
| FY2023 | 2023-12-31 | 23.39M | -54.1% |
| FY2022 | 2022-12-31 | 50.93M | +82.3% |
| FY2021 | 2021-12-31 | 27.94M | — |
Revenue vs competitors
How IDYA compares with its peers on the latest reported figures
- IDYA's LTM Mar 2026 revenue of $225.27M is the 2nd highest of the 9 companies compared; the peer median is $8.36M.
- Its year-over-year change of +3118.1% is the highest of 6, against a peer median of +138.9%.
- Over three fiscal years its annual growth of +62.5% compares with a peer median of +32.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Aug 2026 | $701.94M | +738.8% | +29.5% | |
| LTM Mar 2026 | $225.27M | +3118.1% | +62.5% | |
| LTM Mar 2026 | $49.59M | +395.8% | +128.4% | |
| LTM Mar 2026 | $28.22M | +20.1% | +17.1% | |
| LTM Mar 2026 | $16.72M | +138.9% | — | |
| LTM Jun 2026 | $0 | — | — | |
| LTM Sep 2026 | $0 | — | — | |
| LTM Jun 2026 | $0 | — | — | |
| LTM Sep 2026 | $0 | -100.0% | +35.9% | |
| Peer median (excluding IDYA) | $8.36M | +138.9% | +32.7% | |
Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.94M | 50.93M | 23.39M | 7M | 218.71M |
| Cost of Revenue | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M |
| Gross Profit | 26.22M | 48.83M | 19.38M | 3.17M | 214.12M |
| Gross Margin | 93.8% | 95.9% | 82.9% | 45.2% | 97.9% |
| Research & Development | 58.16M | 89.54M | 129.51M | 294.67M | 314.7M |
| Selling, General & Admin | 18.33M | 21.8M | 24.3M | 35.47M | 63.32M |
| Operating Expenses | 76.48M | 111.33M | 153.81M | 330.14M | 373.43M |
| Depreciation & Amortization | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M |
| EBITDA | (48.04M) | (56.55M) | (108.95M) | (270.64M) | (109.11M) |
| EBITDA Margin | -171.9% | -111.0% | -465.9% | -3866.3% | -49.9% |
| Operating Income | (50.27M) | (62.5M) | (134.43M) | (326.98M) | (159.31M) |
| Operating Margin | -179.9% | -122.7% | -574.9% | -4671.1% | -72.8% |
| Interest Income | 506K | 3.85M | 21.47M | 52.5M | 45.62M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 506K | 3.85M | 21.47M | 52.5M | 45.62M |
| Income Before Tax | (49.76M) | (58.66M) | (112.96M) | (274.48M) | (113.7M) |
| Pre-Tax Margin | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (49.76M) | (58.66M) | (112.96M) | (274.48M) | (113.7M) |
| Net Margin | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| EPS (Basic) | (1.41) | (1.42) | (1.96) | (3.36) | (1.28) |
| EPS (Diluted) | (1.41) | (1.42) | (1.96) | (3.36) | (1.28) |
| Weighted Avg Shares | 35.25M | 41.44M | 57.52M | 81.68M | 88.49M |
| Weighted Avg Shares (Diluted) | 35.25M | 41.44M | 57.52M | 81.68M | 88.49M |
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
Intrinsic Alpha fair value
Locked
Current Price
$26.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.